Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292] or AROAAT2002 [NCT03946449]) can continue to receive fazirsiran every 3 months as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

Official Title

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Keywords

Alpha1-Antitrypsin Deficiency, Liver Diseases, Alpha 1-Antitrypsin Deficiency, Fazirsiran Injection, Fazirsiran 200 mg

Eligibility

Locations

  • UCSD Altman Clinical and Translational Research Institute
    La Jolla California 92037-1337 United States
  • Stanford Medicine Outpatient Center
    Redwood City California 94063 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Takeda
ID
NCT05899673
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 37 study participants
Last Updated